NCT02005289 2025-12-15
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
6 trialsNCT04134936 2024-10-16
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
MorphoSys AG
Phase 1 Completed
NCT01685008 2023-11-07
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)
MorphoSys AG
Phase 2 Completed
NCT02399085 2023-10-23
L-MIND
MorphoSys AG
Phase 2 Completed
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT01161511 2014-04-21
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
Xencor, Inc.
Phase 1 Completed